Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)

Organon

Status and phase: Completed; Phase 3

Conditions: Migraine

Treatments: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day; Drug: Comparator: placebo / Duration of Treatment: 1 day

Study type: Interventional

Funder types: Industry

Identifiers

NCT00095004

0462-066

2004_089

MK0462-066

Details and patient eligibility

About

The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine.

Enrollment: 167 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Six month history of migraine; attacks typically mild when they begin with 1-4 migraine attacks per month.

Exclusion criteria

• Heart disease
• High blood pressure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind